Literature DB >> 9934701

Helper T cell determinant peptide contributes to induction of cellular immune responses by peptide vaccines against hepatitis C virus.

K Hiranuma, S Tamaki, Y Nishimura, S Kusuki, M Isogawa, G Kim, M Kaito, K Kuribayashi, Y Adachi, Y Yasutomi.   

Abstract

The capacity of novel subunit vaccines to generate cytotoxic T lymphocytes (CTLs) against hepatitis C virus (HCV) was assessed. BALB/c mice were immunized with peptides based on the CTL and helper T cell (Th) epitopes of the HCV core, with a mixture of CTL and Th peptides (CTL+Th) or with a conjugated Th-CTL peptide. Mice immunized with CTL, CTL+Th and Th-CTL peptides, but not those immunized with Th peptide, developed HCV core CTL epitope-specific effector cells. Cytotoxic activity induced by immunization with Th-CTL was much higher than that induced by immunization with CTL+Th or CTL alone. However, rapid and high cytotoxic activities against HCV core were not only detected after immunization with peptides containing the CTL epitope but also as a result of infection with recombinant vaccinia virus carrying the HCV core gene after immunization with the Th epitope alone. Immunization with peptides containing the Th epitope also elicited spleen cell proliferation. This study demonstrates the capacity of both Th and CTL activated peptide vaccines to elicit CD8+, MHC class I-restricted CTLs. The capacity of such CTLs to contribute towards a protective and/or pathogenic immune response against HCV can now be assessed in mouse models.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9934701     DOI: 10.1099/0022-1317-80-1-187

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  7 in total

1.  Lipidation of T helper sequences from hepatitis C virus core significantly enhances T-cell activity in vitro.

Authors:  B Langhans; I Braunschweiger; S Schweitzer; G Jung; G Inchauspé; T Sauerbruch; U Spengler
Journal:  Immunology       Date:  2001-04       Impact factor: 7.397

Review 2.  Translating tumor antigens into cancer vaccines.

Authors:  Luigi Buonaguro; Annacarmen Petrizzo; Maria Lina Tornesello; Franco M Buonaguro
Journal:  Clin Vaccine Immunol       Date:  2010-11-03

3.  Suppression of acute viremia by short-term postexposure prophylaxis of simian/human immunodeficiency virus SHIV-RT-infected monkeys with a novel reverse transcriptase inhibitor (GW420867) allows for development of potent antiviral immune responses resulting in efficient containment of infection.

Authors:  K Mori; Y Yasutomi; S Sawada; F Villinger; K Sugama; B Rosenwith; J L Heeney; K Uberla; S Yamazaki; A A Ansari; H Rübsamen-Waigmann
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

Review 4.  Peptides for Vaccine Development.

Authors:  Ian W Hamley
Journal:  ACS Appl Bio Mater       Date:  2022-02-23

5.  DNA vaccination protects mice against challenge with Listeria monocytogenes expressing the hepatitis C virus NS3 protein.

Authors:  Benjamin E Simon; Kenneth A Cornell; Tina R Clark; Sunwen Chou; Hugo R Rosen; Ronald A Barry
Journal:  Infect Immun       Date:  2003-11       Impact factor: 3.441

Review 6.  Interest of Tumor-Specific CD4 T Helper 1 Cells for Therapeutic Anticancer Vaccine.

Authors:  Jeanne Galaine; Christophe Borg; Yann Godet; Olivier Adotévi
Journal:  Vaccines (Basel)       Date:  2015-06-30

Review 7.  Development of Peptide Vaccines in Dengue.

Authors:  Kavita Reginald; Yanqi Chan; Magdalena Plebanski; Chit Laa Poh
Journal:  Curr Pharm Des       Date:  2018       Impact factor: 3.116

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.